Advertisement

Search Results

Advertisement



Your search for Ajay K. Nooka, MD, MPH, FACP,Ajay K. Nooka, MD, MPH, FACP matches 3 pages

Showing 1 - 3


multiple myeloma
immunotherapy

Maintenance Daratumumab After Initial Therapy for Transplant-Eligible Multiple Myeloma: More Questions Than Answers From CASSIOPEIA Part 2

Bortezomib, thalidomide, and dexamethasone (VTd) is an acceptable, effective standard-of-care induction treatment in Europe for patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantation. CASSIOPEIA is a two-part, open-label, randomized, phase III trial in...

multiple myeloma
immunotherapy

Expert Point of View: Ajay K. Nooka, MD, MPH, FACP

Ajay K. Nooka, MD, MPH, FACP, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlanta, considered the presentations on bispecific T-cell–engaging antibodies in myeloma to be...

leukemia
lymphoma
multiple myeloma
immunotherapy

ASH 2020 Meeting Highlights

The world of hematologic malignancies continues to move forward at a robust pace despite the challenges of the COVID era. Although some areas of clinical trials and basic research suffered short-term stoppages or delays due to the pandemic, the studies presented at the 2020 American Society of...

Advertisement

Advertisement



Advertisement